ERBB2 and breast cancer: Within the same study, in a prospective cohort of 35 plasma samples, the EV signature achieved an accuracy of 85.2% for discrimination between progressive disease and partial response/stable disease and showed similar performance for classifying treatment response when applied to different BC subtypes, HR+, HER2+ and TNBC.